Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-PAT: Postpartum Antihypertensive Treatment for Preeclampsia
NCT04298034Phase 3Active, not recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Jul 2020
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of labetalol and nifedipine GITS in preeclampsia (2 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Hospital Readmission at 6 weeks. Started Jul 2020; status: active, not recruiting.
02
Drugs
labetalolnifedipine GITS
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT04298034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04298034.